Literature DB >> 19580342

Nuclear topography of the 1q21 genomic region and Mcl-1 protein levels associated with pathophysiology of multiple myeloma.

S Legartova1, J Krejci, A Harnicarova, R Hajek, S Kozubek, E Bartova.   

Abstract

Chromosomal rearrangements and copy number variation are frequently observed in cancer cells, including multiple myeloma (MM). Karyotypic abnormalities seen in MM cells correlate with the disease stage and drug responses. Here, we investigate the nuclear arrangement of the 1q21 region; amplification of this region is an important diagnostic and prognostic marker of MM. We examined the lymphoblastoid cell line CD138- ARH-77, multiple myeloma CD138+ MOLP-8 cells, and the CD138+ bone marrow fraction of patients diagnosed with MM. In this experimental system, we observed that gamma-radiation and selected cytostatic drugs such as melphalan and dexamethasone did not significantly alter the nuclear radial arrangement of the 1q21 region and other relevant regions of chromosome 1. Similarly, conserved nuclear radial positioning after cytostatic treatment was observed for the c-myc, TP53, CCND1, and IgH loci. When analyzed Mcl-1, a protein encoded by a gene mapped to the 1q21 region, we found that the variant Mcl1S is highly expressed in multiple myeloma MOLP-8 cells, but not in peripheral blood lymphocytes of healthy donors or lymphoblastoid ARH-77 cells; this is in contrast to the expression pattern of the Mcl-1L variant. On the basis of these observations we suggest that the 1q21 region is an important diagnostic marker of MM, particularly the gene encoding the Mcl-1S variant, which can be easily detected by western analysis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19580342     DOI: 10.4149/neo_2009_05_404

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  3 in total

1.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

Review 2.  Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer.

Authors:  Natalie Yan Li Ngoi; Clarice Choong; Joanne Lee; Gregory Bellot; Andrea Li Ann Wong; Boon Cher Goh; Shazib Pervaiz
Journal:  Cancers (Basel)       Date:  2020-03-02       Impact factor: 6.639

Review 3.  Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications.

Authors:  Ignacio J Cardona-Benavides; Cristina de Ramón; Norma C Gutiérrez
Journal:  Cells       Date:  2021-02-05       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.